Shanghai RAAS(SZ:002252) Zheng Quan Ri Bao·2025-10-27 23:19Core Viewpoint - The company has announced its profit distribution plan for the first three quarters of 2025, aiming to enhance shareholder returns while ensuring sufficient liquidity for operations and growth [20][21][24]. Financial Data - For the first nine months of 2025, the company reported a net profit attributable to shareholders of 1,470,738,960.56 yuan, with the parent company achieving a net profit of 953,611,770.21 yuan [21][24]. - The total distributable profit as of September 30, 2025, is 11,175,120,755.02 yuan, after accounting for previously paid cash dividends of 217,371,383.70 yuan [21][24]. Profit Distribution Plan - The proposed distribution plan suggests a cash dividend of 0.153 yuan per share (including tax) for every 10 shares held, which is expected to total approximately 100,515,842.14 yuan [21][22][24]. - The plan will be implemented within two months after approval at the shareholders' meeting, with adjustments made if the total share capital changes before the distribution [22][24]. Shareholder Engagement - The company emphasizes its commitment to enhancing shareholder returns and maintaining a long-term investment perspective, aligning with its operational and strategic goals [24][25]. - The board and supervisory committee have reviewed and approved the profit distribution plan, ensuring compliance with relevant regulations [26][27][41]. Clinical Trials and Product Development - The company is advancing its clinical trials for the SR604 injection, which has received regulatory approval for various phases, indicating ongoing investment in product development [14][17][18]. - The SR604 injection aims to address bleeding prevention in patients with hemophilia and has recently applied for additional indications [17][18]. Employee Stock Ownership Plan - The company has approved the unlocking of shares under its first employee stock ownership plan, reflecting its strategy to align employee interests with company performance [50][54]. - The plan's conditions have been met for a significant number of participants, indicating a successful implementation of the employee incentive strategy [50][54]. Strategic Direction - The company is focused on becoming a leading biopharmaceutical enterprise through innovation and strategic acquisitions, aiming for sustainable growth in the blood products industry [24][25]. - The dual strategy of internal growth and external acquisitions is designed to enhance operational capabilities and market position [24].